tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TSE:GUD Stock Latest News

Knight Therapeutics announces NIKTIMVO regulatory submission in Brazil
The FlyKnight Therapeutics announces NIKTIMVO regulatory submission in Brazil
10d ago
INCY
Knight Therapeutics announces Health Canada approval for WYNZORA
PremiumThe Fly
Knight Therapeutics announces Health Canada approval for WYNZORA
2M ago
Knight Therapeutics Reports Record Revenues Amid Challenges
PremiumCompany Announcements
Knight Therapeutics Reports Record Revenues Amid Challenges
4M ago
Knight Therapeutics Reports Record Q3 Revenues and Raises Guidance
PremiumCompany Announcements
Knight Therapeutics Reports Record Q3 Revenues and Raises Guidance
4M ago
Knight Therapeutics Achieves Record-High Revenues in Q3 2025
PremiumCompany Announcements
Knight Therapeutics Achieves Record-High Revenues in Q3 2025
4M ago
Knight Therapeutics reports Q3 EPS (C$0.04) vs. (C$0.00) last year
PremiumThe FlyKnight Therapeutics reports Q3 EPS (C$0.04) vs. (C$0.00) last year
4M ago
Knight Therapeutics sees FY25 revenue C$430M-C$440M
Premium
The Fly
Knight Therapeutics sees FY25 revenue C$430M-C$440M
4M ago
Knight Therapeutics (KHTRF) Q3 Earnings Cheat Sheet
Premium
Pre-Earnings
Knight Therapeutics (KHTRF) Q3 Earnings Cheat Sheet
4M ago
Knight Therapeutics Secures US$100 Million Credit Facility to Boost Growth
PremiumCompany Announcements
Knight Therapeutics Secures US$100 Million Credit Facility to Boost Growth
4M ago
Knight Therapeutics announces approval, launch of MINJUVI in Argentina
PremiumThe Fly
Knight Therapeutics announces approval, launch of MINJUVI in Argentina
4M ago
INCY
Knight Therapeutics announces relaunch of MYFEMBREE in Canada
PremiumThe Fly
Knight Therapeutics announces relaunch of MYFEMBREE in Canada
5M ago
Knight Therapeutics announces relaunch of ORGOVYX in Canada
PremiumThe Fly
Knight Therapeutics announces relaunch of ORGOVYX in Canada
5M ago
Knight Therapeutics announces normal course issuer bid
PremiumThe FlyKnight Therapeutics announces normal course issuer bid
6M ago
Knight Therapeutics’ Earnings Call Highlights Growth and Expansion
Premium
Company Announcements
Knight Therapeutics’ Earnings Call Highlights Growth and Expansion
7M ago
Knight Therapeutics: Strong Financial Performance and Strategic Positioning Justify Buy Rating
Premium
Ratings
Knight Therapeutics: Strong Financial Performance and Strategic Positioning Justify Buy Rating
7M ago
Knight Therapeutics Reports Record Revenue Amid Net Loss
PremiumCompany Announcements
Knight Therapeutics Reports Record Revenue Amid Net Loss
7M ago
Knight Therapeutics Achieves Record Revenues Amid Strategic Expansions
PremiumCompany Announcements
Knight Therapeutics Achieves Record Revenues Amid Strategic Expansions
7M ago
Knight Therapeutics reports Q2 EPS (C$0.13) vs. (C$0.02) last year
PremiumThe Fly
Knight Therapeutics reports Q2 EPS (C$0.13) vs. (C$0.02) last year
7M ago
Knight Therapeutics sees FY25 revenue C$410M-C$420M
PremiumThe Fly
Knight Therapeutics sees FY25 revenue C$410M-C$420M
7M ago
Knight Therapeutics announces CREXONT regulatory submission in Mexico
PremiumThe FlyKnight Therapeutics announces CREXONT regulatory submission in Mexico
7M ago
AMRX
Knight Therapeutics announces CREXONT NDS accepted for Health Canada review
Premium
The Fly
Knight Therapeutics announces CREXONT NDS accepted for Health Canada review
7M ago
AMRX
Knight Therapeutics closes acquisition of Paladin
Premium
The Fly
Knight Therapeutics closes acquisition of Paladin
9M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >